Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morganti, A.
Right arrow Articles by Strata, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morganti, A.
Right arrow Articles by Strata, M.
J Am Soc Nephrol 13:S187-S189, 2002
© 2002 American Society of Nephrology

Treatment of Atherosclerotic Renal Artery Stenosis

Alberto Morganti, Chiara Bencini, Cecilia Del Vecchio and Maria Strata

Cattedra di Medicina Interna and Centro Ipertensione Arteriosa, Ospedale San Paolo and Centro Fisiologia Clinica e Ipertensione, Ospedale Maggiore, University of Milan, Italy.

Correspondence to Prof. Alberto Morganti, Centro Fisiologia Clinica e Ipertensione, Ospedale Maggiore, Milano, Via F. Sforza, 35, 20122 Milano Italy. Phone: 0039-02-55033506; Fax: 0039-02-5457666;

ABSTRACT. The increasing prevalence of atherosclerotic renal artery stenosis (ARAS) has prompted in recent years a more aggressive treatment of this condition for reducing BP and for preserving the jeopardized renal function. Percutaneous transluminal renal angioplasty (PTRA), alone or in conjunction with stent implantation, may be useful for both these goals. However, despite the methodological improvements that make this procedure much safer than surgery, caution must be applied before PTRA is extended to all patients with ARAS. Indeed, PTRA is associated with a 23% rate of major/minor complications and with a 20% rate of restenosis, even in arteries implanted with stent. Moreover the cure rate of hypertension achievable with PTRA is, at best, around 10%, with a 40% rate of improvements. Even for rescuing the ischemic kidney, PTRA/stent implantation are not always effective; only 35% of patients with ARAS have some improvement in renal function. These data indicate that there is an urgent need of rigorous criteria for selecting among the many patients with ARAS those who may actually benefit from the dilation procedure. E-mail: alberto.morganti@unimi.it




This article has been cited by other articles:


Home page
 Am. J. Roentgenol.Home page
J. P. Bolduc, V. L. Oliva, E. Therasse, M.-F. Giroux, L. Bouchard, P. Perreault, A. Cliche, and G. Soulez
Diagnosis and Treatment of Renovascular Hypertension: A Cost-Benefit Analysis
Am. J. Roentgenol., March 1, 2005; 184(3): 931 - 937.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
L. A. Weinrauch and J. A. D'Elia
Renal artery stenosis: "fortuitous diagnosis," problematic therapy
J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1614 - 1616.
[Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673